Lexapro vs. Zoloft: A Psychiatrist Compares Two SSRIs

Lexapro and Zoloft belong to the same drug class, share a similar mechanism of action, and are both considered first-line treatments for major depressive disorder. The biggest difference is the breadth of their FDA-approved uses. Lexapro is approved for two conditions: major depressive disorder and generalized anxiety disorder. Zoloft is approved for a much wider range of conditions, including major depressive disorder, panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), social anxiety disorder, and premenstrual dysphoric disorder (PMDD). The chart below shows where each drug is officially indicated and where it is commonly prescribed off-label.

Sertraline carries more FDA approvals across anxiety-spectrum conditions, including OCD, panic disorder, social anxiety disorder, PTSD, and PMDD.

Escitalopram holds approvals for major depressive disorder in adults and adolescents and for generalized anxiety disorder in both adults and children aged 7 and older. Off-label prescribing remains common and evidence-based for both medications, but the approved indication often shapes which drug a clinician reaches for first.

Both medications are selective serotonin reuptake inhibitors (SSRIs). They block the reabsorption of serotonin in the brain, which keeps more of the neurotransmitter available between nerve cells. Serotonin influences mood, anxiety regulation, sleep, appetite, and even gastrointestinal motility, and enhancing its activity has been associated with improving depressive and anxious symptoms. By extending serotonin's signaling window, SSRIs gradually reset the chemical environment that drives those symptoms.

Where the two drugs diverge is in receptor specificity. Escitalopram is the purified S-enantiomer of citalopram and is considered one of the most selective SSRIs on the market. Its unique action at allosteric sites of the serotonin transporter may produce slightly higher serotonin availability than other SSRIs at equivalent doses. Sertraline, by contrast, has a small but measurable effect on dopamine transporters in addition to serotonin, which some clinicians view as advantageous for individuals whose depression presents with low motivation or anhedonia.

Even so, the absolute differences between the two are modest, and individual response varies considerably.

Side effects from SSRIs, if they occur, typically appear within the first one to two weeks and most ease as the body adjusts. Most are also mild, but they can shape day-to-day quality of life and influence whether individuals stay on a medication long enough to benefit.

Common Side Effects

Both Lexapro and Zoloft can cause nausea, headache, dry mouth, fatigue, sweating, sexual dysfunction, and disrupted sleep. Sertraline tends to produce more gastrointestinal complaints, particularly diarrhea, in the first weeks of treatment. Escitalopram is generally associated with somewhat milder GI effects but a slightly higher rate of sedation and weight gain.

Weight Gain

Weight change is one of the most-asked-about differences between these two medications. A 2024 target trial emulation study comparing eight first-line antidepressants found that escitalopram use was associated with roughly a 15% higher risk of gaining at least 5% of baseline weight at six months than sertraline use. The average difference was small (escitalopram users gained about 0.9 pounds more than sertraline users at six months) but for individuals concerned about weight gain, the distinction may matter.

Sexual Side Effects

Sexual dysfunction, including reduced libido, delayed orgasm, and erectile difficulties, is a known class effect of SSRIs and can contribute to treatment discontinuation. A review in Mental Health Clinician found rates were highest with paroxetine (another SSRI), while sertraline and escitalopram had lower rates. A more recent systematic review and meta-analysis suggests SSRIs as a class significantly increase the risk of orgasmic dysfunction and reduced sexual satisfaction compared with placebo.

Serious but Rare Risks

Both medications carry the SSRI class boxed warning for increased suicidal thoughts in individuals under 25 during the first weeks of treatment. Both can also cause serotonin syndrome when combined with other serotonergic drugs, hyponatremia (low sodium) in older adults, and, in rare cases, abnormal heart rhythms (QT prolongation), with escitalopram showing slightly more cardiac signal at higher doses. Discontinuation symptoms can occur with either drug if stopped abruptly, which is why tapering should be supervised by a clinician.

Choosing between Lexapro and Zoloft is a decision only a psychiatric practitioner has the training and clinical context to make, given the many factors that determine which SSRI is right for a given person. Diagnosis, prior medication history, family response to specific antidepressants, current side effect tolerance, age, life stage, co-occurring physical conditions, other medications and supplements, and personal goals all factor into the selection. Two individuals with the same symptoms can land on different medications for legitimate clinical reasons, and the same individual may need a different SSRI at a different point in life. A thorough psychiatric evaluation is the only reliable way to match the right medication to the right person.

Pregnancy and Postpartum

Both medications are considered safe for pregnant women and their babies. Sertraline has long been widely considered the preferred SSRI during pregnancy and while nursing, based on the breadth of safety data accumulated over its three-decade history of use. Both drugs cross into breast milk in small amounts, but sertraline's lower transfer rate has historically made it the default. Anyone considering antidepressant treatment during pregnancy should review options with both their psychiatrist and OB/GYN, particularly if postpartum depression treatment is the goal.

Older Adults

Adults over 65 metabolize SSRIs more slowly. Escitalopram's half-life is roughly 50% longer in older individuals, which is why a 10 mg daily dose is the typical maximum in this age group. Both medications can also raise the risk of hyponatremia and falls in older adults, so close monitoring during initiation and dose changes is standard practice.

Drug Interactions

Neither drug should be combined with monoamine oxidase inhibitors, other SSRIs or SNRIs, or St. John's Wort due to the risk of serotonin syndrome. Sertraline has a notable interaction with pimozide and other QT-prolonging antipsychotics. Escitalopram interacts with amiodarone and certain antifungals. NSAIDs and anticoagulants increase bleeding risk with either medication. A complete medication and supplement list should be reviewed at every medication management appointment to flag possible conflicts before they become clinical problems.

When Neither Is the Right Fit

Some people do not respond fully to either drug. In those cases, clinicians may switch to a different SSRI, a serotonin-norepinephrine reuptake inhibitor (SNRI) such as duloxetine, an atypical antidepressant such as bupropion, or augmentation strategies. For treatment-resistant depression, options expand to include TMS therapy and esketamine. The right next step depends on which symptoms remain and which side effects shaped the original prescription.

Lexapro is FDA-approved for only two conditions, but its real-world prescribing footprint is much wider. Off-label prescribing refers to a clinician using a medication for a condition the FDA has not formally approved it to treat. The practice is legal, common, and often supported by strong clinical evidence. It typically happens when a drug shows efficacy for a condition in published research but has not gone through the additional regulatory steps needed for a formal FDA indication. For escitalopram, decades of post-approval studies have built a substantial off-label evidence base across the anxiety and mood disorder spectrum.

The breadth of off-label use is one reason Lexapro shows up in so many treatment plans despite its narrow FDA labeling. Escitalopram is frequently prescribed off-label for obsessive-compulsive disorder, body dysmorphic disorder, panic disorder, post-traumatic stress disorder, social phobia, premenstrual dysphoric disorder, premature ejaculation, eating disorders, and vasomotor symptoms associated with menopause. The conditions below represent the most evidence-supported off-label applications.

Panic Disorder

Panic disorder is an off-label indication for escitalopram. Although Zoloft holds the FDA approval here, a randomized controlled trial found that Lexapro reduces panic attack frequency and severity at doses of 10 to 20 mg daily. The selectivity of escitalopram at the serotonin transporter makes it a frequent first-choice off-label option for individuals who cannot tolerate sertraline.

Social Anxiety Disorder

Social anxiety disorder responds well to either SSRI, but escitalopram has accumulated extensive trial data supporting its off-label use. Clinicians often select it for individuals whose social anxiety overlaps with generalized anxiety, since Lexapro is FDA-approved for GAD and addresses both presentations with one medication.

OCD and PTSD

Obsessive-compulsive disorder and post-traumatic stress disorder are both within Zoloft's FDA indication list, yet escitalopram is widely prescribed off-label for both. The clinical decision usually hinges on prior medication response, family history, and side effect tolerance. Many individuals who cannot tolerate sertraline's gastrointestinal effects often respond well to escitalopram for OCD and PTSD symptoms, particularly when combined with exposure-based therapy.

PMDD and Premenstrual Symptoms

Premenstrual dysphoric disorder is an FDA-approved indication for sertraline but remains one of escitalopram's most established off-label uses. Clinical trials have shown both continuous and luteal-phase dosing regimens can reduce mood, irritability, and physical symptoms associated with PMDD.

Vasomotor Symptoms of Menopause

One of the more unusual off-label applications of escitalopram is for hot flashes and night sweats associated with menopause. A randomized controlled trial found that escitalopram 10 to 20 mg daily reduced daily hot flash frequency by an average of 4.6 episodes compared with 3.2 on placebo over 8 weeks, with 55% of women experiencing at least a 50% reduction. For individuals who cannot or prefer not to use hormone therapy, escitalopram may be considered a non-hormonal treatment option for vasomotor symptoms.

Other Off-Label Applications

Beyond the major indications above, escitalopram is occasionally prescribed off-label for body dysmorphic disorder, binge eating disorder, bulimia nervosa, premature ejaculation, and insomnia secondary to a mood or anxiety disorder. Each of these uses should be discussed with a psychiatrist who can weigh the evidence base, expected timeline, and side effect tradeoffs against alternative treatments. Off-label does not mean experimental, but it does mean the conversation about expected benefit and risk should be especially clear before starting.

Lexapro and Zoloft remain two of the most reliable, well-studied SSRIs in modern psychiatry, and the choice between them is rarely about which is universally better. It’s about which one fits a specific person, a specific diagnosis, and a specific life stage. Outcomes data from a 2026 LifeStance treatment study show that 79% of individuals experienced clinically significant improvement in anxiety symptoms and 73% in depression symptoms*, a reminder that medication paired with ongoing care often produces meaningful change.

Lexapro and Zoloft are prescribed only when clinically appropriate and should only be taken as prescribed under the supervision of a licensed healthcare provider.

*amongst 140,000 LifeStance patients with at least moderate anxiety and 150,000 with at least moderate depression